COMPASS PATHWAYS PLC Retained Earnings
COMPASS PATHWAYS PLC (CMPS) had Retained Earnings of -$985.19 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-05
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$985.19M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$731.39M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$822.59M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$728.72M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$985.19M 10-Q · filed 2026-08-05 |
| 2026-03-31 | -$731.39M 10-Q · filed 2026-05-13 |
| 2025-12-31 | -$822.59M 10-Q · filed 2026-08-05 |
| 2025-09-30 | -$728.72M 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$591.00M 10-Q · filed 2025-07-31 |
| 2025-03-31 | -$552.60M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$534.73M 10-K · filed 2026-03-24 |
| 2024-09-30 | -$491.40M 10-Q · filed 2024-10-31 |
| 2024-06-30 | -$452.90M 10-Q · filed 2024-08-01 |
| 2024-03-31 | -$414.80M 10-Q · filed 2024-05-08 |
| 2023-12-31 | -$379.61M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$347.08M 10-Q · filed 2023-11-02 |
| 2023-06-30 | -$313.69M 10-Q · filed 2023-08-03 |
| 2023-03-31 | -$285.35M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$261.15M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$230.22M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$211.85M 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$190.81M 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$169.64M 10-K · filed 2023-02-28 |
| 2021-09-30 | -$143.99M 6-K · filed 2021-11-09 |
| 2021-06-30 | -$128.14M 6-K · filed 2021-08-11 |
| 2020-12-31 | -$97.90M 10-K · filed 2022-02-24 |
| 2019-12-31 | -$37.56M 20-F · filed 2021-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |